COVID-19 pandemic had impacted the reporting of notifiable communicable diseases. Since the beginning of the pandemic and the introduction of relate public health measures, notifications for most notifiable diseases have declined compared to previous years. In this study, we aim to quantify the changes in the incidences of notifiable infectious diseases during and after the pandemic in Siracusa Local Health Authority, Italy. We collected and analysed the infectious disease notifications made in two different three-years periods, 2017-2019 and 2020-2022 in Siracusa Local Health Authority, Italy. Descriptive statistics were used to find the percentages and the 95% confidence interval (CI). Exact “F-tests” was performed to compare the mean values between the studied periods to evaluate the hypothesis that the number of reported cases would not differ significantly between the two periods. Significance was assessed at the p < 0.05 level. The total number of notifications significantly decreased by 69.3% in the pandemic period compared to the pre-pandemic one, with the highest reduction of air-borne transmission diseases (-86.5%), followed by food-borne diseases (-68.2%) and sexually transmitted diseases (-39.3%). Conversely, an increase in number of notifications was found only for legionellosis. The COVID-19 pandemic had the potential to influence communicable disease reporting at multiple points. While the effects could vary considerably, the results would be expected to reduce the number and the detection of notifiable cases. Included would be changes in exposures, diagnostic testing, reporting to public health agencies, and public health investigations.
Objectives: The introduction of universal prophylaxis with Nirsevimab represents a major innovation in preventing respiratory syncytial virus (RSV) infections in newborns. In Sicily, Nirsevimab administration began on 1 November 2024, for all newborns under one year and at-risk infants during the 2024–2025 season. This study assessed the real-world impact of this strategy in reducing RSV-related hospitalizations. Methods: This retrospective cohort study examined newborns residing in Sicily from 2015 to May 2025, evaluating hospitalization incidence rates attributable to RSV during the first year of life. RSV hospitalizations were identified using ICD-9 codes (079.6, 466.11, 480.1) in any diagnostic position. Incidence rates in the 2024–2025 season (intervention period) were compared with preceding seasons. Results: During the study period, 4431 RSV hospitalization cases occurred (19.84 cases per 1000 person-years), peaking in 2023–2024 (53.47 cases per 1000 person-years). A statistically significant 40% reduction in RSV hospitalizations was observed during the 2024–2025 season (October–April) compared with the preceding season, with a relative reduction ranging between 33.4% and 54.8% across sensitivity models. Conclusions: These results confirm the significant impact of the universal prophylaxis program in real-world practice, consistent with other European programs. These findings support universal RSV prevention strategies and provide insights for optimizing regional and national health policies.
Background/Objectives: Influenza poses a substantial global public health challenge, disproportionately affecting vulnerable populations. Vaccination is the most effective preventive measure, and recent strategies in Italy emphasize the principle of “appropriateness”—the alignment of specific vaccine formulations (e.g., adjuvanted or high-dose) with targeted risk groups to optimize protection. Nevertheless, challenges persist in ensuring the consistent administration of the most suitable vaccine, particularly among high-risk individuals who would benefit most. Methods: A retrospective descriptive study was conducted using data from the 2023–2024 and 2024–2025 influenza vaccination campaigns of the Local Health Authority of Catania. Vaccination data were analyzed by age group and vaccine type, based on national immunization guidelines. Population categories included individuals ≥ 65 years, adults 60–64 years, adults 18–59 years (with/without chronic conditions), children, and pregnant/postpartum women. Vaccine types analyzed were aQIV, QIV-HD, QIV-SD, QIVcc, and LAIV. Descriptive statistics were used, and Relative Risk (RR) with 95% Confidence Intervals (CI) was calculated using the 60–64 age group as a reference. Analyses were performed with Stata 18.0. Results: In 2023–2024, 78.8% of individuals ≥ 65 received recommended vaccines, compared to 100% in the 60–64 group (RR = 0.23; 95% CI: 0.225–0.231). Adults 18–59, children, and pregnant/postpartum women showed ≥99% adherence. In 2024–2025, appropriateness in the ≥65 group improved to 96.1% (RR = 0.12; 95% CI: 0.118–0.128). All other groups maintained high adherence (≥99%), except for 6.2% of children aged 6 months–2 years who inappropriately received LAIV. Conclusions: Despite dramatically improved vaccination appropriateness in the elderly, a persistent and critical safety issue--inappropriate administration LAIV use in 6.2% of young children—highlights the need for targeted interventions to ensure complete patient safety.
Chemical pollution poses a significant threat to human health, with detrimental effects on various physiological systems, including the respiratory, cardiovascular, mental, and perinatal domains. While the impact of pollution on these systems has been extensively studied, the intricate relationship between chemical pollution and immunity remains a critical area of investigation. The focus of this study is to elucidate the relationship between chemical pollution and human immunity. To accomplish this task, this study presents a comprehensive review that encompasses in vitro, ex vivo, and in vivo studies, shedding light on the ways in which chemical pollution can modulate human immunity. Our aim is to unveil the complex mechanisms by which environmental contaminants compromise the delicate balance of the body’s defense systems going beyond the well-established associations with defense systems and delving into the less-explored link between chemical exposure and various immune disorders, adding urgency to our understanding of the underlying mechanisms and their implications for public health.